Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Intangibles (2016 - 2025)

Sunshine Biopharma's Intangibles history spans 6 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Intangibles rose 25.64% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, up 25.64%, while the annual FY2025 figure was $3.8 million, 25.64% up from the prior year.
  • Intangibles reached $3.8 million in Q4 2025 per SBFM's latest filing, up from $2.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $3.8 million in Q4 2025 to a low of $776856.0 in Q4 2022.
  • Average Intangibles over 4 years is $2.2 million, with a median of $2.1 million recorded in 2024.
  • Peak YoY movement for Intangibles: soared 135.89% in 2024, then fell 28.05% in 2025.
  • A 4-year view of Intangibles shows it stood at $776856.0 in 2022, then surged by 85.91% to $1.4 million in 2023, then skyrocketed by 109.08% to $3.0 million in 2024, then rose by 25.64% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Intangibles are $3.8 million (Q4 2025), $2.1 million (Q3 2025), and $2.5 million (Q2 2025).